BALLOON OSTIAL DILATION FOR TREATMENT OF CHRONIC SINUSITIS

Similar documents
ENDOBRONCHIAL ULTRASOUND FOR DIAGNOSIS AND STAGING OF LUNG CANCER

PANCREATIC ISLET TRANSPLANT

IMMUNE CELL FUNCTION ASSAY

GENETIC TESTING FOR PREDICTING RISK OF NONFAMILIAL BREAST CANCER

GENETIC TESTING FOR TAMOXIFEN TREATMENT

HEMATOPOIETIC CELL TRANSPLANTATION FOR EPITHELIAL OVARIAN CARCINOMA

MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES

GENETIC TESTING FOR KRAS, NRAS AND BRAF VARIANT ANALYSIS IN METASTATIC COLORECTAL CANCER

PROTEOMIC TESTING FOR SYSTEMIC THERAPY IN NON-SMALL-CELL LUNG CANCER

DRUG TESTING IN PAIN MANAGEMENT AND SUBSTANCE USE DISORDER(S) TREATMENT

RADIOFREQUENCY ABLATION OF PRIMARY OR METASTATIC LIVER TUMORS

INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION

LARTRUVO (olaratumab)

MULTIMARKER SERUM TESTING RELATED TO OVARIAN CANCER

FECAL ANALYSIS IN THE DIAGNOSIS OF INTESTINAL DYSBIOSIS

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 10/04/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

RADIOFREQUENCY ABLATION OF MISCELLANEOUS SOLID TUMORS EXCLUDING LIVER TUMORS

OPTICAL COHERENCE TOMOGRAPHY (OCT) OF THE MIDDLE EAR

NOVEL BIOMARKERS IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

ORAL IMPLANT PROCEDURES

ALPHA1-PROTEINASE INHIBITORS

NEGATIVE PRESSURE WOUND THERAPY

INTRACAVITARY BALLOON BRACHYTHERAPY FOR MALIGNANT AND METASTATIC BRAIN TUMORS

INTERSPINOUS FIXATION (FUSION) DEVICES

GENETIC TESTING FOR HEREDITARY HEARING LOSS

NUTRIENT OR NUTRITIONAL PANEL TESTING

ENTYVIO (vedolizumab)

CONTINUOUS OR INTERMITTENT GLUCOSE MONITORING IN INTERSTITIAL FLUID

NASAL AIRWAY EVALUATION Acoustic Reflex Technology Acoustic Rhinometry Optical Rhinometry Rhinomanometry Sleep Sonography

DERMATOLOGIC APPLICATIONS OF PHOTODYNAMIC THERAPY

CARDIOVASCULAR RISK PANELS

GENETIC TESTING FOR MARFAN SYNDROME, THORACIC AORTIC ANEURYSMS AND DISSECTIONS AND RELATED DISORDERS

INTRAVITREAL IMPLANTS

HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY AMYLOIDOSIS

TRANSMYOCARDIAL REVASCULARIZATION

GENETIC TESTING FOR FANCONI ANEMIA

PERCUTANEOUS TIBIAL NERVE STIMULATION

DYNAMIC SPINAL VISUALIZATION

PERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES

STELARA (ustekinumab)

GENE EXPRESSION PROFILING AND PROTEIN BIOMARKERS FOR PROSTATE CANCER MANAGEMENT

GENETIC TESTING FOR NEUROFIBROMATOSIS

BLINCYTO (blinatumomab)

PERCUTANEOUS BALLOON KYPHOPLASTY, RADIOFREQUENCY KYPHOPLASTY, AND MECHANICAL VERTEBRAL AUGMENTATION

MYLOTARG (gemtuzumab ozogamicin)

GATTEX (teduglutide [rdna origin])

PERCUTANEOUS TIBIAL NERVE STIMULATION

GENETIC TESTING WITH MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES

RELISTOR (methylnaltrexone bromide) INJECTION FOR SUBCUTANEOUS USE

TREATMENTS FOR GAUCHER DISEASE

DEEP BRAIN STIMULATION

CIMZIA (certolizumab pegol)

APOKYN (apomorphine hydrochloride)

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

SOMATULINE DEPOT (lanreotide acetate)

GENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA

INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE

ELECTRIC TUMOR TREATMENT FIELDS

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

BIVENTRICULAR PACEMAKER (CARDIAC RESYNCHRONIZATION THERAPY) FOR THE TREATMENT OF HEART FAILURE

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

TYMLOS (abaloparatide)

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME BRCA1 BRCA2

PARSABIV (etelcalcetide)

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

BRINEURA (cerliponase alfa)

HEMATOPOIETIC CELL TRANSPLANTATION FOR SOLID TUMORS OF CHILDHOOD

PERCUTANEOUS TRANSCATHETER CLOSURE OF PARAVALVULAR LEAK

VYXEOS (daunorubicin and cytarabine)

ELECTROMYOGRAPHY (EMG) AND NERVE CONDUCTION STUDIES (NCS)

HEMATOPOIETIC CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA

LIMB COMPRESSION DEVICES FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

H.P. ACTHAR GEL (repository corticotropin injection)

BREAST RECONSTRUCTION/REMOVAL AND REPLACEMENT OF IMPLANTS

ALPHA-FETOPROTEIN-L3 FOR DETECTION OF HEPATOCELLULAR CANCER

BONIVA (ibandronate sodium)

GENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)

TYSABRI FOR CROHN S DISEASE

HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 12/19/17 SECTION: MEDICINE LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/14/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

INTRAOPERATIVE RADIATION THERAPY

VESTIBULAR FUNCTION TESTING

KYMRIAH (tisagenlecleucel)

MEASUREMENT OF EXHALED NITRIC OXIDE AND EXHALED BREATH CONDENSATE

DECISIONDx BIOMARKER TESTS

ACTEMRA (tocilizumab)

STRENSIQ (asfotase alfa)

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

RADIOFREQUENCY ABLATION OR CRYOABLATION FOR ESOPHAGEAL DISORDERS

LUXTURNA (voretigene neparovec-rzyl)

COSENTYX (secukinumab)

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

YESCARTA (axicabtagene ciloleucel)

CAROTID ARTERY ANGIOPLASTY

NONINVASIVE TECHNIQUES FOR EVALUATION AND MONITORING OF CHRONIC LIVER DISEASE

ALLERGY TESTING AND TREATMENT

COMPLEMENTARY AND ALTERNATIVE MEDICINE

Transcription:

BALLOON OSTIAL DILATION FOR TREATMENT OF CHRONIC SINUSITIS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Medical Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines. The section identified as Description defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage. The section identified as Criteria defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational. State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity. Medical Coverage Guidelines are subject to change as new information becomes available. For purposes of this Medical Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable. BLUE CROSS, BLUE SHIELD and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ. Description: Balloon ostial dilation (also known as balloon sinuplasty) has been investigated in the treatment of sinusitis. A balloon catheter is placed in the sinus ostium and the balloon is inflated to stretch the opening and improve sinus drainage. General anesthesia may be required to minimize individual s discomfort. O518.16.docx Page 1 of 5

Criteria: For functional endoscopic sinus surgery, see BCBSAZ Medical Coverage Guideline #O1009, Functional Endoscopic Sinus Surgery. Balloon sinuplasty for the treatment of sinusitis is considered experimental or investigational based upon: 1. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes, and 2. Insufficient evidence to support improvement of the net health outcome, and 3. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives, and 4. Insufficient evidence to support improvement outside the investigational setting. Resources: Literature reviewed 03/20/18. We do not include marketing materials, poster boards and nonpublished literature in our review. The BCBS Association Medical Policy Reference Manual (MPRM) policy is included in our guideline review. References cited in the MPRM policy are not duplicated on this guideline. 1. 7.01.105 BCBS Association Medical Policy Reference Manual. Balloon Ostial Dilation for Treatment of Chronic Sinusitis. Re-issue date 02/08/2018, issue date 07/20/2006. 2. American Academy of Otolaryngology - Head and Neck Surgery. Sinus Balloon Catheterization Position Statement. 03/05/2007. 3. American Academy of Otolaryngology - Head and Neck Surgery. Dilation of Sinuses, Any Method (Balloon). 06/28/2010. 4. American Rhinologic Society. Sinuplasty. 5. External Consultant Review. Ear, Nose and Throat. 12/16/2013. 6. Melroy CT. Sinuplasty. American Rhinologic Society. 2015. 7. Payne SC, Stolovitzky P, Mehendale N, et al. Medical therapy versus sinus surgery by using balloon sinus dilation technology: A prospective multicenter study. American journal of rhinology & allergy. Jul 2016;30(4):279-286. O518.16.docx Page 2 of 5

Resources: (cont.) 8. Rudmik L, Holy CE, Smith TL. Geographic variation of endoscopic sinus surgery in the United States. Laryngoscope. Aug 2015;125(8):1772-1778. 9. Sillers MJ, Lay KF, Holy CE. In-office balloon catheter dilation: analysis of 628 patients from an administrative claims database. Laryngoscope. Jan 2015;125(1):42-48. 10. Soler ZM, Rudmik L, Hwang PH, Mace JC, Schlosser RJ, Smith TL. Patient-centered decision making in the treatment of chronic rhinosinusitis. Laryngoscope. Oct 2013;123(10):2341-2346. 11. Stankiewicz J, Truitt T, Atkins J, et al. Two-year results: transantral balloon dilation of the ethmoid infundibulum. Int Forum Allergy Rhinol. Feb 15 2012. 12. TEC Clearinghouse News. Update on Balloon Sinuplasty: American Rhinologic Society Position Statement. Oct.13, 2006. 13. UpToDate.com. Chronic rhinosinusitis: Management. 08/01/2016, 10/22/2015. 14. Vaughan WC. Review of balloon sinuplasty. Curr Opin Otolaryngol Head Neck Surg. 2008 Feb;16(1):2-9. O518.16.docx Page 3 of 5

Non-Discrimination Statement: Blue Cross Blue Shield of Arizona (BCBSAZ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. BCBSAZ provides appropriate free aids and services, such as qualified interpreters and written information in other formats, to people with disabilities to communicate effectively with us. BCBSAZ also provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, call (602) 864-4884 for Spanish and (877) 475-4799 for all other languages and other aids and services. If you believe that BCBSAZ has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, you can file a grievance with: BCBSAZ s Civil Rights Coordinator, Attn: Civil Rights Coordinator, Blue Cross Blue Shield of Arizona, P.O. Box 13466, Phoenix, AZ 85002-3466, (602) 864-2288, TTY/TDD (602) 864-4823, crc@azblue.com. You can file a grievance in person or by mail or email. If you need help filing a grievance BCBSAZ s Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, 1 800 368 1019, 800 537 7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html Multi-Language Interpreter Services: O518.16.docx Page 4 of 5

Multi-Language Interpreter Services: (cont.) O518.16.docx Page 5 of 5